Sodium zirconium cyclosilicate
- Generic Name
- Sodium zirconium cyclosilicate
- Brand Names
- Lokelma
- Drug Type
- Small Molecule
- Chemical Formula
- Na2O9Si3Zr
- CAS Number
- 17141-74-1
- Unique Ingredient Identifier
- D652ZWF066
- Background
Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that acts as a highly selective potassium removing agent. It is administered orally and is odorless, tasteless, and stable at room temperature. Approval of the medi...
- Indication
Sodium zirconium cyclosilicate is a potassium binder indicated for the treatment of hyperkalemia in adult patients.
- Associated Conditions
- Hyperkalemia
- Associated Therapies
- -
A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients
- Conditions
- Interventions
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-10-21
- Target Recruit Count
- 94
- Registration Number
- NCT06578078
- Locations
- 🇪🇸
Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain
🇪🇸Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain
🇪🇸Hospital Universitario Nuestra Señora del Perpétuo Socorro, Albacete, Spain
Keeping RAASi Treatment With Optimal Potassium Control
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-08-29
- Target Recruit Count
- 78
- Registration Number
- NCT06578533
- Locations
- 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸Hospital General Universitario Dr. Balmis, Alicante, Spain
🇪🇸Hospital Universitario Vall d'Hebrón, Barcelona, Spain
Sodium Zirconium Cyclosilicate to Allow Liberal Fruit and Vegetable Intake for Patients With CKD Stage 3b and 4
- Conditions
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Leiden University Medical Center
- Target Recruit Count
- 16
- Registration Number
- NCT06365684
Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy
- Conditions
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 62
- Registration Number
- NCT05382988
The ORTIZ Study: Optimising RASi Therapy With SZC
- Conditions
- Interventions
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Barts & The London NHS Trust
- Target Recruit Count
- 10
- Registration Number
- NCT04983979
- Locations
- 🇬🇧
Kieran Mccafferty, London, Uk, United Kingdom
OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2021-03-09
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Michael Fu
- Target Recruit Count
- 110
- Registration Number
- NCT04789239
- Locations
- 🇸🇪
Sahlgrenska University Hospital-Ostra Hospital, Gothenburg, Sweden
Study to Assess the Effect of Sodium Zirconium Cyclosilicate on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2021-03-09
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 62
- Registration Number
- NCT04788641
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 39
- Registration Number
- NCT04727528
- Locations
- 🇵🇷
Research Site, San Juan, Puerto Rico
Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone
- Conditions
- Interventions
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 366
- Registration Number
- NCT04676646
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Comparison of Potassium Binders in the ER
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 120
- Registration Number
- NCT04585542
- Locations
- 🇺🇸
University of California, Irvine Medical Center, Orange, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.